Perigon Wealth Management, LLC Vertex Pharmaceuticals Inc Transaction History

Perigon Wealth Management, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 29, 2024	BUY	$343.0 - $410.68 $2,744 - $3,285	8 Added 0.56%	1,432 $582,000
Q3 2023 Oct 30, 2023	SELL	$338.18 - $362.46 $41,934 - $44,945	-124 Reduced 8.01%	1,424 $495,000
Q2 2023 Aug 02, 2023	BUY	$314.42 - $351.91 $67,914 - $76,012	216 Added 16.22%	1,548 $544,000
Q1 2023 May 03, 2023	SELL	$283.23 - $323.1 $115,274 - $131,501	-407 Reduced 23.4%	1,332 $419,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $42,006 - $47,257	147 Added 9.23%	1,739 $502,000
Q3 2022 Dec 13, 2022	SELL	$273.83 - $305.53 $284,235 - $317,140	-1,038 Reduced 39.47%	1,592 $461,000
Q2 2022 Aug 11, 2022	SELL	$234.96 - $292.55 $237,544 - $295,768	-1,011 Reduced 27.77%	2,630 $741,000
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $116,466 - $137,270	526 Added 16.89%	3,641 $950,000
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $78,592 - $99,211	444 Added 16.62%	3,115 $684,000
Q3 2021 Nov 01, 2021	BUY	$181.39 - $202.99 $484,492 - $542,186	2,671 New	2,671 $484,000
Q3 2021 Oct 25, 2021	SELL	$181.39 - $202.99 $569,564 - $637,388	-3,140 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$187.49 - $221.1 $186,740 - $220,215	996 Added 46.46%	3,140 $633,000
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $290,449 - $338,557	1,403 Added 189.34%	2,144 $461,000
Q4 2020 Jan 28, 2021	BUY	$207.01 - $276.09 $153,394 - $204,582	741 New	741 $175,000
Q2 2018 Aug 07, 2018	SELL	$145.72 - $169.96 $9,471 - $11,047	-65 Closed	0 $0
Q3 2017 Dec 05, 2017	BUY	$148.13 - $162.24 $9,628 - $10,545	65 New	65 $10,000
Q3 2011 Nov 14, 2022	SELL	N/A	-1,038	1,592 $461,000

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Perigon Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Perigon Wealth Management, LLC with notifications on news.